Press Releases :: Channel Therapeutics Corporation (CHRO)

Skip to main content Skip to section navigation Skip to footer

May 01, 2025 5:00 PM EDT

Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules

Apr 17, 2025 6:00 AM EDT

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

Dec 20, 2024 9:00 AM EST

Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine

Dec 18, 2024 8:30 AM EST

Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model

Nov 21, 2024 9:49 AM EST

Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates

Oct 29, 2024 8:30 AM EDT

Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain

Oct 28, 2024 8:00 AM EDT

Chromocell to Present at Upcoming Fall Investor Conferences

Oct 24, 2024 8:45 AM EDT

Chromocell Announces Amendment to Stock Repurchase Plan

Sep 03, 2024 9:00 AM EDT

Chromocell to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 07, 2024 8:45 AM EDT

Chromocell Announces Stock Repurchase Plan

Select a page:

rss_feed News RSS